RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin(Université de Bordeaux), Chiara Ambrogio(Dana-Farber Cancer Institute)
Cited by 54
Related Papers
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
|Annals of Oncology|2022|100
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
|Cell Reports Medicine|2024|20
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
|Research Square|2023|5